Protocol: CDISCPILOT01                                                                  Page  1 of 3 
Population: Intent-to-Treat 
Table 14-2.01 
Summary of Demographic and Baseline Characteristics 
 
 
[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-
square test for categorical variables. 
NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first 
definite symptoms of Alzheimer's disease. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas                     21:02 Monday, June 26, 2006 
 
Placebo 
(N=86) 
Xanomeline 
Low Dose 
(N=84) 
Xanomeline
High Dose
(N=84) 
Total 
(N=254) 
p-value
[1] 
 
Age (y) 
n 
 86 
 84 
 84 
254 
 0.5934
 
Mean 
 75.2 
 75.7 
 74.4 
 75.1 
 
 
SD 
  8.59 
  8.29 
  7.89 
  8.25 
 
 
Median 
 76.0 
 77.5 
 76.0 
 77.0 
 
 
Min 
 52.0 
 51.0 
 56.0 
 51.0 
 
 
Max 
 89.0 
 88.0 
 88.0 
 89.0 
 
 
 
<65 yrs 
 14 ( 16%)   8 ( 10%)  11 ( 13%)  33 ( 13%)
 0.1439
 
65-80 yrs 
 42 ( 49%)  47 ( 56%)  55 ( 65%) 144 ( 57%)
 
 
>80 yrs 
 30 ( 35%)  29 ( 35%)  18 ( 21%)  77 ( 30%)
 
 
Sex 
n 
 86 
 84 
 84 
254 
 0.1409
 
Male 
 33 ( 38%)  34 ( 40%)  44 ( 52%) 111 ( 44%)
 
 
Female 
 53 ( 62%)  50 ( 60%)  40 ( 48%) 143 ( 56%)
 
 
Race (Origin) 
n 
 86 
 84 
 84 
254 
 0.6477
 
Caucasian 
 75 ( 87%)  72 ( 86%)  71 ( 85%) 218 ( 86%)
 
 
African Descent 
  8 (  9%)   6 (  7%)   9 ( 11%)  23 (  9%)
 
 
Hispanic 
  3 (  3%)   6 (  7%)   3 (  4%)  12 (  5%)
 
 
Other 
  0 
  0 
  1 (  1%)   1 ( <1%)
 
 
MMSE 
n 
 86 
 84 
 84 
254 
 0.5947
 
Mean 
 18.0 
 17.9 
 18.5 
 18.1 
 
 
SD 
  4.27 
  4.22 
  4.16 
  4.21 
 
 
Median 
 19.5 
 18.0 
 20.0 
 19.0 
 

--- Page 2 ---
Protocol: CDISCPILOT01                                                                  Page  2 of 3 
Population: Intent-to-Treat 
Table 14-2.01 
Summary of Demographic and Baseline Characteristics 
 
 
[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-
square test for categorical variables. 
NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first 
definite symptoms of Alzheimer's disease. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas                     21:02 Monday, June 26, 2006 
 
Placebo 
(N=86) 
Xanomeline 
Low Dose 
(N=84) 
Xanomeline
High Dose
(N=84) 
Total 
(N=254) 
p-value
[1] 
 
Min 
 10.0 
 10.0 
 10.0 
 10.0 
 
 
Max 
 23.0 
 24.0 
 24.0 
 24.0 
 
 
Duration of disease n 
 86 
 84 
 84 
254 
 0.1530
 
Mean 
 42.7 
 48.7 
 40.5 
 43.9 
 
 
SD 
 30.24 
 29.58 
 24.69 
 28.40 
 
 
Median 
 35.3 
 40.3 
 36.0 
 36.3 
 
 
Min 
  7.2 
  7.8 
  2.2 
  2.2 
 
 
Max 
183.1 
130.8 
135.0 
183.1 
 
 
 
<12 months 
  5 (  6%)   3 (  4%)   4 (  5%)  12 (  5%)
 0.7885
 
>=12 months 
 81 ( 94%)  81 ( 96%)  80 ( 95%) 242 ( 95%)
 
 
Years of education 
n 
 86 
 84 
 84 
254 
 0.3875
 
Mean 
 12.6 
 13.2 
 12.5 
 12.8 
 
 
SD 
  2.95 
  4.15 
  2.92 
  3.38 
 
 
Median 
 12.0 
 12.0 
 12.0 
 12.0 
 
 
Min 
  6.0 
  3.0 
  6.0 
  3.0 
 
 
Max 
 21.0 
 24.0 
 20.0 
 24.0 
 
 
Baseline weight(kg) n 
 86 
 83 
 84 
253 
 0.0030
 
Mean 
 62.8 
 67.3 
 70.0 
 66.6 
 
 
SD 
 12.77 
 14.12 
 14.65 
 14.13 
 
 
Median 
 60.6 
 64.9 
 69.2 
 66.7 
 
 
Min 
 34.0 
 45.4 
 41.7 
 34.0 
 
 
Max 
 86.2 
106.1 
108.0 
108.0 
 

--- Page 3 ---
Protocol: CDISCPILOT01                                                                  Page  3 of 3 
Population: Intent-to-Treat 
Table 14-2.01 
Summary of Demographic and Baseline Characteristics 
 
 
[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-
square test for categorical variables. 
NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first 
definite symptoms of Alzheimer's disease. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas                     21:02 Monday, June 26, 2006 
 
Placebo 
(N=86) 
Xanomeline 
Low Dose 
(N=84) 
Xanomeline
High Dose
(N=84) 
Total 
(N=254) 
p-value
[1] 
 
Baseline height(cm) n 
 86 
 84 
 84 
254 
 0.1262
 
Mean 
162.6 
163.4 
165.8 
163.9 
 
 
SD 
 11.52 
 10.42 
 10.13 
 10.76 
 
 
Median 
162.6 
162.6 
165.1 
162.9 
 
 
Min 
137.2 
135.9 
146.1 
135.9 
 
 
Max 
185.4 
195.6 
190.5 
195.6 
 
 
Baseline BMI 
n 
 86 
 83 
 84 
253 
 0.0133
 
Mean 
 23.6 
 25.1 
 25.3 
 24.7 
 
 
SD 
  3.67 
  4.27 
  4.16 
  4.09 
 
 
Median 
 23.4 
 24.3 
 24.8 
 24.2 
 
 
Min 
 15.1 
 17.7 
 13.7 
 13.7 
 
 
Max 
 33.3 
 40.1 
 34.5 
 40.1 
 
 
 
<25 
 59 ( 69%)  47 ( 56%)  44 ( 52%) 150 ( 59%)
 0.2326
 
25-<30 
 21 ( 24%)  27 ( 32%)  28 ( 33%)  76 ( 30%)
 
 
>=30 
  6 (  7%)  10 ( 12%)  12 ( 14%)  28 ( 11%)
 
 
